How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anesthesia-maintenance-propofol-remifentanil-cisatracurium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Anesthesia maintenance , propofol,remifentanil,cisatracurium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anesthesia maintenance , propofol,remifentanil,cisatracurium (Anesthesia maintenance , propofol,remifentanil,cisatracurium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker). Area: Ane

marketed General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Anesthesia maintenance , propofol,remifentanil,cisatracurium (Anesthesia maintenance , propofol,remifentanil,cisatracurium) — Second Affiliated Hospital of Xi'an Jiaotong University. This anesthetic regimen combines a GABA-A agonist (propofol), an opioid mu-receptor agonist (remifentanil), and a neuromuscular blocking agent (cisatracurium) to induce unconsciousness, analgesia, and muscle paralysis for surgical procedures.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anesthesia maintenance , propofol,remifentanil,cisatracurium TARGET	Anesthesia maintenance , propofol,remifentanil,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) class)

Second Affiliated Hospital of Xi'an Jiaotong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anesthesia maintenance , propofol,remifentanil,cisatracurium — Competitive Intelligence Brief. https://druglandscape.com/ci/anesthesia-maintenance-propofol-remifentanil-cisatracurium. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab